Clinical utility of hla-b*58:01 genotyping to prevent allopurinol-induced sjs/ten

Lavu, Alekhya and Thiriveedi, Sneha and Thomas, Levin and Khera, Kanav and Saravu, Kavitha and Rao, Mahadev (2021) Clinical utility of hla-b*58:01 genotyping to prevent allopurinol-induced sjs/ten. Hospital Pharmacy, 56 (6). pp. 660-663.

[img] PDF
00014156.pdf - Published Version
Restricted to Registered users only

Download (299kB) | Request a copy


Purpose: A 28-year-old male reported to our hospital with Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/ TEN) overlap syndrome that developed as an adverse drug reaction (ADR) to allopurinol. HLA-B*58:01 allele is associated with an increased risk of developing allopurinol-induced SJS/TEN. Methods: Genomic DNA was extracted from peripheral blood leukocytes. DNA sequencing was done using SANGER sequencing method. Results: Pharmacogenetic testing results revealed positive for HLA-B*58:01 allele. Symptoms of the patient receded after allopurinol withdrawal. Conclusion: The thrust of personalized therapy is from decoding the individual specific genetic variations astutely for better therapeutic outcomes such as reducing the ADRs. Pharmacogenetic testing is emerging as a safe, fast, and economic screening tool for personalized therapy by preventing ADRs. Pharmacogenetic HLA-B*58:01 allele testing before allopurinol administration could significantly reduce the incidence of SJS/TEN and associated mortalities/ morbidities and thereby represent a potential cost-effective intervention.

Item Type: Article
Uncontrolled Keywords: Adverse drug reactions; analgesics; Skin; medication safety; gene therapy.
Subjects: Medicine > KMC Manipal > Medicine
Pharmacy > MCOPS Manipal > Pharmacy Practice
Depositing User: KMC Library
Date Deposited: 29 Dec 2021 08:50
Last Modified: 29 Dec 2021 08:50

Actions (login required)

View Item View Item